Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
$0.01
$0.01
$1.12
$430K1.91N/AN/A
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
$0.01
$0.01
$0.00
$0.05
$403K-1.08662 shsN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
$8.00
+28.9%
$5.81
$1.25
$145.46
$152K2.781,920 shs8,701 shs
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
$0.01
$0.01
$0.01
$0.56
$389K1.061.11 million shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
0.00%0.00%0.00%0.00%0.00%
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
0.00%0.00%0.00%-41.24%-70.92%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
-31.05%-37.32%+3.43%+121.63%+1,551,300.00%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
0.00%0.00%-11.09%-42.47%-98.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/AN/AN/AN/AN/AN/AN/AN/A
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
1.9048 of 5 stars
3.23.00.00.00.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
0.00
N/AN/AN/A
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
0.00
N/AN/AN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.00
N/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
2.33
Hold$1.7517,793.66% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
$10.62M0.00N/AN/A($2.00) per share0.00
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
N/AN/AN/AN/A($0.01) per shareN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/A($493.34) per shareN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/AN/AN/AN/A$0.33 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
$48.29M$1.320.00N/AN/A498.04%N/A-76.15%N/A
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
-$240KN/A0.00N/AN/AN/A-4,015.59%N/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
-$1.82MN/A0.00N/AN/A-3,652.66%-971.09%N/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
-$51.06M-$1.10N/AN/AN/A-1,899.61%-114.21%N/A

Latest PPCB, GLGLF, NXEN, and VIRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/A-$0.06N/A-$0.05N/A$2.20 million
5/15/2025Q3 2025
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/A-$12.50N/A-$12.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/AN/AN/AN/AN/A
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
N/AN/AN/AN/AN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/A
0.21
0.19
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
N/A
0.02
0.02
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.01
2.24
2.24
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/A
0.76
0.76

Institutional Ownership

CompanyInstitutional Ownership
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/A
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
N/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
31.37%

Insider Ownership

CompanyInsider Ownership
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/A
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
30.60%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.10%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
10.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
1238.39 millionN/ANot Optionable
Nexien Biopharma, Inc. stock logo
NXEN
Nexien Biopharma
470.77 million49.12 millionNot Optionable
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
119,00019,000Not Optionable
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
2039.74 million35.50 millionNo Data

Recent News About These Companies

Viracta Therapeutics Shuts Down Operations, Lays Off All Staff
Viracta Therapeutics terminates employees, to wind down operations
Viracta Therapeutics Announces Wind Down of Operations
Viracta Therapeutics Inc (VIRX) Stock Trading Recap
VIRX’s Unexpected Surge: What’s Next?

Media Sentiment Over Time

GLG Life Tech stock logo

GLG Life Tech OTCMKTS:GLGLF

GLG Life Tech Corporation researches for, develops, grows, refines, and produces natural sweeteners extracted from the stevia plant and monk fruit in Canada and internationally. It also offers P-Pro Plus, a pea protein product; REB M GOLD, a bioconverted Rebaudioside M and Rebaudioside D. sweetener; and natural ingredients. It serves in the food and beverage industry. The company was formerly known as GLG Life Tech Limited and changed its name to GLG Life Tech Corporation in March 2007. GLG Life Tech Corporation was incorporated in 1998 and is headquartered in Richmond, Canada.

Nexien Biopharma stock logo

Nexien Biopharma OTCMKTS:NXEN

$0.0057 0.00 (0.00%)
As of 08/8/2025

Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

Propanc Biopharma stock logo

Propanc Biopharma OTCMKTS:PPCB

$8.00 +1.79 (+28.92%)
As of 03:44 PM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Viracta Therapeutics stock logo

Viracta Therapeutics NASDAQ:VIRX

$0.0098 0.00 (0.00%)
As of 07/25/2025

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.